Volume 29, Number 6—June 2023
CME ACTIVITY - Synopsis
Neurologic Complications of Babesiosis, United States, 2011–2021
Sara Locke1, Jane O’Bryan1, Adeel S. Zubair, Melissa Rethana, Anne Spichler Moffarah, Peter J. Krause2, and Shelli F. Farhadian2
Table 2
Imaging indications and findings in patients with neurologic symptoms associated with babesiosis admitted to Yale-New Haven Hospital, New Haven, Connecticut, USA, January 2011–October 2021*
| Imaging | No. (%) patients |
|---|---|
| Neuroimaging modality | |
| Computed tomography | 28 (17.2) |
| Magnetic resonance imaging | 7 (4.3) |
| Electroencephalogram |
2 (1.2) |
| Indication | |
| Altered mental status/confusion | 15 (9.2) |
| Headache | 8 (4.9) |
| Fever | 5 (3.1) |
| Evaluate CNS abnormalities | 3 (1.8) |
| Weakness | 3 (1.8) |
| Dizziness | 1 (0.6) |
| Dysphagia, slurred speech | 1 (0.6) |
| Fall | 1 (0.6) |
| Head injury | 1 (0.6) |
| Visual changes | 1 (0.6) |
| Syncope | 1 (0.6) |
| Numbness | 1 (0.6) |
| Fatigue | 1 (0.6) |
| Seizure |
1 (0.6) |
| Findings | |
| Nonspecific white matter changes | 23 (14.1) |
| Volume loss | 14 (8.6) |
| Acute changes | 2 (1.2) |
| Evidence of previous stroke | 3 (1.8) |
*Total sample consisted of 163 patients. Neuroimaging modalities and indications sum to >33 because some patients received multiple imaging modalities or had multiple indications. CNS, central nervous system.
1These first authors contributed equally to this article.
2These senior authors contributed equally to this article.
Page created: April 13, 2023
Page updated: May 19, 2023
Page reviewed: May 19, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.